GlassScriptPhysician profile
Amanda Horacek
NPI 1104389121
$5,113.38
in general payments reported to CMS, 2019-2025
22 companies · $842 in 2025
The $842 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $994 · 2022: $1,053 · 2023: $1,328 · 2024: $897 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,066.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,910.49 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $684.65 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Nestle Healthcare Nutrition INC. | $454.40 | 2021-2023 | |
| Janssen Biotech, INC. | $347.80 | 2022-2025 | Tremfya, Stelara, Simponi |
| Phathom Pharmaceuticals, INC. | $219.77 | 2024 | Voquezna |
| Lilly USA, LLC | $185.87 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $164.97 | 2023-2025 | Dupixent |
| Genzyme Corporation | $142.34 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $140.10 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.58 | 2024-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $116.83 | 2022 | |
| Inspire Medical Systems, INC. | $115.25 | 2023 | Inspire |
| Teva Pharmaceuticals USA, INC. | $112.58 | 2025 | Austedo Xr |
| Alexion Pharmaceuticals, INC. | $96.54 | 2021 | |
| Medtronic, INC. | $71.09 | 2023 | Interstim |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $51.50 | 2025 | Ibsrela |
| Qol Medical, LLC | $50.62 | 2023-2025 | Sucraid |
| Madrigal Pharmaceuticals | $38.23 | 2025 | Rezdiffra |
| Redhill Biopharma INC. | $24.95 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.62 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $16.37 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.83 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Horacek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.